Go to Health Care Provider version
| Diagnosis | Neuroblastoma | Study Status | Closed to enrollment |
| Phase | I |
| Age | Child, Adult - (2 Year to 21 Years) | Randomisation | YES |
| Line of treatment | Disease relapse or progression |
| Routes of Treatment Administration | LY3295668/Erbumine taken by mouth (capsules)
Topotecan and cyclophosphamide will be given intravenously |
| Last Posted Update | 2022-03-01 |
| ClinicalTrials.gov # | NCT04106219 |
International Sponsor
Eli Lilly and CompanyPrincipal Investigators for Canadian Sites
The Hospital for Sick Children - Daniel MorgensternCentres
Study Description
The reason for this study is to see if the study medication LY3295668 erbumine is safe in participants with relapsed/refractory neuroblastoma (neuroblastoma that has come back or is not improving despite treatment). LY3295668 erbumine blocks a protein called Aurora kinase A. Aurora kinase A is thought to contribute to the aggressiveness of neuroblastoma cells.
The medication will be given either alone or in combination with chemotherapy.
Inclusion Criteria
- Age between 2 and 21 years
- Neuroblastoma that has come back (relapse) or is not improving despite treatments (refractory)
- The child must be able to swallow capsules
- Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team
